Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Study of Concurrent Chemoradiotherapy With Temozolomide Versus Radiation Therapy Alone in Patients With IDH Wild-type/TERT Promoter Mutation Grade II/III Gliomas

NCT02766270 is registered in ClinicalTrials.gov with Beijing Tiantan Hospital as lead sponsor.

NCT NCT02766270
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02766270 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Study of Concurrent Chemoradiotherapy With Temozolomide Versus Radiation Therapy Alone in Patients With IDH Wild-type/TERT Promoter Mutation Grade II/III Gliomas
Lead sponsor
Beijing Tiantan Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
September 26, 2016
Completion date
December 31, 2018
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

grade ii/iii glioma